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Background to the debate: This PLoS Medicine Debate
examines the different approaches that can be taken to
tackle neglected tropical diseases (NTDs). Some commen-
tators, like Jerry Spiegel and colleagues from the
University of British Columbia, feel there has been too
much focus on the biomedical mechanisms and drug
development for NTDs, at the expense of attention to the
social determinants of disease. Burton Singer argues that
this represents another example of the inappropriate
‘‘overmedicalization’’ of contemporary tropical disease
control. Peter Hotez and colleagues, in contrast, argue
that the best return on investment will continue to be
mass drug administration for NTDs.
Viewpoint by Jerry Spiegel, Shafik Dharamsi,
Kishor Wasan, and Annalee Yassi: A Proportion of
Research Funding Should Be Diverted to
Addressing Social Determinants of NTDs
The past decade has seen a host of new initiatives and funding
to address NTDs affecting the world’s poorest people [1-4]. But
despite this additional funding, the global disease burden remains
high [5]. We believe that one of the reasons for this continuing
burden is that NTD research has neglected the broad social
determinants of disease. We propose a mechanism, a ‘‘social offset
in research,’’ to address this neglect.
NTD initiatives have primarily aimed to stimulate drug
development by offering incentives for pharmaceutical companies
to produce essential medicines for vulnerable populations [6-9].
These initiatives have largely ignored other manifestations of
neglect, such as the weak health systems and poor socio-
environmental conditions that cause and/or perpetuate NTDs.
One problem with excessive focus on developing new drugs is that
it diverts attention and funding away from complementary
strategies needed to sustainably reduce disease burden [10,11].
Examples of such strategies include (1) improving access to clean
water, good sanitation, and adequate housing and (2) community
education and mobilization to apply measures needed for effective
prevention, such as community-based vector control and training
of health workers in infection control measures.
One way to redirect attention and funding toward such
complementary strategies is through a type of ‘‘social offset’’ in
NTD research. We propose that whenever a research program on
an NTD innovation is funded, a proportion of the funding is set
aside (‘‘offset’’) to address related socio-environmental and health
system aspects. The concept of ‘‘social offsets’’ emerged recently in
response to the need for affordable housing in some urban areas
undergoing gentrification [12]. When low-income residents
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developers were asked to pay a ‘‘social offset,’’ i.e. contribute to
a fund that invests in affordable housing for low-income people.
The idea derives from the notion of ‘‘carbon offsets’’ (to
compensate for carbon-producing activities such as air travel,
one pays into a fund that mitigates carbon production by investing
in clean energy technology or planting trees). In our proposal, we
are suggesting that any investment in a narrow biomedical solution
is offset by channeling a proportion of that investment into
broader approaches for reducing the NTD burden.
We feel this approach is timely, given recent debates on
whether vertical (disease-specific) funding has been counterpro-
ductive by drawing resources away from public health systems
strengthening and preventive measures [13-15]. The Commis-
sion on Social Determinants of Health [16] has highlighted the
importance of ‘‘non-medical determinants of health,’’ but these
determinants have yet to be integrated into global strategies for
NTD control. Such control requires both a biomedical approach
and a broader socio-environmental and health systems ap-
proach. Our social offsets proposal could be a bridge between
the two.
Such integrated approaches are of proven effectiveness, but they
have been sidelined recently by over-reliance on biomedical
‘‘solutions.’’ Singer and de Castro note that a century ago the
Rockefeller Foundation funded two approaches to hookworm
control: treating those infected and addressing the social and
environmental determinants of disease by installing sanitary
facilities [17,18]. A similar, integrated approach is now needed
for many other NTDs. For example, nobody questions the need
for better drugs for visceral leishmaniasis (the focus of coauthor
KMW’s research) [19], but complementary prevention initiatives,
health system strengthening, and improved diagnostics are all
equally important for disease control [20]. Yet most research
funding in the US for leishmaniasis is devoted to basic research,
biomedical innovations, and product development (66.3%),
compared to 3.7% for epidemiological research and only 7.1%
for implementation research [21].
Merely strengthening incentives to make new medicines more
accessible for NTDs [22] still ignores the need for complex health
intervention trials that take social and environmental conditions
into account and militates against an integrated approach.
Recognizing this, the NTD research initiative of our university
(University of British Columbia) is explicitly shifting its focus from
‘‘drug development and delivery’’ toward effective disease-
reducing interventions [23].
What would our ‘‘social offsets’’ proposal involve? Inspired by
the ‘‘15 by 2015’’ campaign that urges donor organizations to
allocate 15% of their vertical funding toward sustainable
comprehensive primary health care [24], we call for a proportion
of NTD research funding to be allocated to financing complex
health intervention trials. Specific percentages can vary according
to the particular disease and context.
This social offsets approach parallels the way in which some
economic development projects have started to consider issues
such as sustainability and community well-being. Such projects
don’t just assess financial costs and benefits, but also consider
direct and indirect social and environmental impacts [25,26]. We
believe that it is time to extend this kind of thinking to drug
development. Before products are licensed, proponents should not
only affirm clinical safety and effectiveness, but also consider the
social, environmental, and health systems contexts into which the
new drug will be introduced. They should accordingly be required
to invest in research that will ensure that introducing their product
on the market will have an overall benefit in reducing the burden
of the disease in question.
Our proposal builds upon the creative funding initiatives begun
by the NTDs movement. It will introduce a mechanism analogous
to carbon offsets or to the environmental impact assessments
conducted as part of some economic development projects. While
much discussion is needed to work out the details, a ‘‘social offsets’’
approach could help conquer NTDs and improve health equity.
Viewpoint by Burton Singer: Bring Back Primary
Prevention for Relieving the Burden of NTDs
The recent designation of a set of tropical diseases as
‘‘neglected’’ [27] has given rise to a groundswell of interest in
strategies for their control and research on new tools for alleviation
of their burden [28-30]. Regrettably, this initiative has also served
to expose yet another example of the over-medicalization of
contemporary tropical disease control strategies. A primary
example is the emphasis on drug administration alone to alleviate
the burden of schistosomiasis [31-33] and the soil-transmitted
helminths, of which hookworm is the most prominent [34]. The
extant programs focus on deworming already infected people
while doing nothing to prevent reworming of the same individuals.
These programs amount to establishing a chain of dependence on
drugs with no terminal horizon in sight. The problem is that at
some point funds for drugs and their programmatic support fade
out [35], and the reworming process escalates afresh.
Reading a bit of history is instructive on this issue. You don’t
find a demand for drugs to treat hookworm in the southern United
States today, because an integrated program of drugs to treat
infected cases and installation of toilets (a tool for prevention) as a
route for human feces—initially containing hookworm eggs—put
an end to the problem almost a century ago. It is worthwhile
reading the 1921 annual report of the Rockefeller Foundation and
the autobiographical paper by Charles Stiles [36], who ran the
hookworm eradication program in the southern US, to get a clear
picture of how sanitary engineering can play a basic role in
prevention of the corpus of soil-transmitted helminthic diseases on
the current NTD list.
Shifting to schistosomiasis, we again have a major drugs-only
effort [31-33] that could be dramatically improved by cooperative
ventures between combinations of the many engineering groups
that are currently providing clean water at the village level in the
tropics (http://www.globalwaterchallenge.org/home/, http://
www.ewb-international.org, http://thewaterproject.org) and the
contemporary health personnel who seem to see schistosomiasis
control as something to be dealt with by installing an endless chain
of dependence on pharmacological agents.
These examples are a useful vantage point from which to re-
emphasize a much broader theme: namely, that nearly half of the
measurable population-level health improvements in sub-Saharan
Africa in the 1990s were a consequence of positive inputs in water
and sanitation, housing, transportation, and communication [37].
The focus is on the disease prevention consequences of
infrastructure improvements. An important feature of such
interventions is that they act on multiple diseases simultaneously.
This is of great importance due to the pervasiveness of coinfection
in the tropics [38,39]. Clean water and effective sanitary facilities
can simultaneously prevent schistosomiasis and the entire corpus
of soil-transmitted helminths on the NTD list. Thus, steps forward
toward sustainably reducing the burden of many NTDs are
dependent on building bridges between the infrastructure
suppliers, rooted in engineering, and the health sector. Financing
of reductions in NTDs by preventive measures can be piggybacked
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involved and where the health sector is presently not engaged.
A useful example of this kind of cooperative venture derives
from the concession agreement between the Nam Theun Power
Company (NTPC) and the government of Laos PDR [40]. Here a
Health Impact Assessment—associated with dam construction and
implementation of the Nam Theun 2 Hydroelectric Project—and
a Public Health Action Plan [41], together with NTPC
implementation of regular health assessments for resettled
communities and provision of improved housing with clean water
and sanitary facilities, is dealing not only with NTDs, but with the
full gamut of health problems of the local people [42]. An
important reason for mentioning this direct linkage of infrastruc-
ture development to health issues is that it exemplifies the kind of
project that currently goes essentially unnoticed in international
health circles. However, this was not always the case. Bridge
building between corporate development projects in the tropics
and public health were facilitated from 1950 to 1978 by a
stimulating series of conferences held at the Harvard School of
Public Health [43] under the title ‘‘Industry and Tropical Health.’’
These meetings engaged industry representatives with public
health people on problems of mutual concern. Regrettably, the
vanishing of this series has left a large void for 30 years or more
that, under proper leadership, could readily be filled at the present
time. The repair of this broken bridge could provide an important
base for the financing and implementation of prevention
interventions that could substantially reduce the burden of many
NTDs.
Viewpoint by Peter J. Hotez, Christy Hanson, and
Donald A. P. Bundy: The Promise of Integrated
NTD Control
More than one billion people, mostly in the developing world,
suffer from one or more of the neglected tropical diseases (NTDs)
[44,45]. These diseases disproportionately impact poor and rural
populations who lack access to safe water, adequate sanitation, and
essential medicines. Ninety percent of the global burden of NTDs
is caused by a group of seven highly prevalent diseases:
onchocerciasis, lymphatic filariasis (LF), trachoma, schistosomiasis,
and the three major soil-transmitted helminth (STH) infections
(hookworm, roundworm, and whipworm) [44,45]. In terms of
both health impact and cost-effectiveness, few other interventions
can rival mass drug administration for NTDs, and increasingly this
approach is being recognized for its beneficial effects on
strengthening health systems, improving economic development,
and achieving the Millennium Development Goals [45].
Considerable progress has been made in the control of the
individual diseases through focused programs [44]. Since the
1970s the Onchocerciasis Control Program (OCP) and its follow-
on African Programme for Onchocerciasis Control (APOC) have
been successful in controlling blindness in sub-Saharan Africa and
actually eliminating the disease in Mali and Senegal [44,46].
Through free drugs provided by Merck (ivermectin, trade name
Mectizan) and annual community-directed drug treatments with
ivermectin (CDTI) it is projected that by 2010 OCP and APOC
will have protected over 150 million individuals from blindness in
over 30 countries, and at an economic rate of return expected to
reach 18% [47]. Simultaneously, APOC has amassed an army of
almost 400,000 volunteer community drug distributors to extend
the reach of local health systems [44]. Similarly through mass drug
administration of ivermectin or diethylcarbamazine citrate (DEC)
together with albendazole (from GlaxoSmithKline) the Global
Programme to Eliminate LF has treated almost 2 billion people
over the past 8 years, thereby averting 32 million disability-
adjusted life years [48], and at a cost of only $14–$30 per DALY
averted [49]. The active transmission of LF has also been
interrupted in several countries [50]. Through Pfizer donations
of azithromycin the International Trachoma Initiative operates
control programs in 15 countries [44,51].
Despite this progress, individuals and communities commonly
remain affected by NTDs, as there is considerable epidemiological
overlap of these diseases. In more than 75% of countries in Africa,
at least six of the seven diseases coexist in some fashion across
communities. Today only 9%–21% of children who could benefit
from benzimidazole anthelminthics actually receive such essential
STH medicines [53], while fewer than 2% of eligible people
receive praziquantel for schistosomiasis [44]. School-based
deworming programs show particular promise in this role [53].
One of the great public health challenges in the coming decade
will be to accelerate the expansion of mass drug administration for
STH infections and schistosomiasis, bringing it up to the level of
coverage of LF, onchocerciasis, and trachoma, even as these
control programs are being extended to reach all at-risk
populations.
How then can we ensure sustainability for control or elimination
of all of the seven most common NTDs? The solution may, in part,
be found in the efficiencies of integrated preventive chemotherapy
conducted while longer-term water, sanitation, and development
infrastructure is built. Historically, Ministries of Health in disease-
endemic countries have supported the control of NTDs through
parallel programs. For example, it is not unusual to find a national
schistosomiasis control program managed alongside a national LF
control program, each with its own plan, funding stream, drug
supply chain systems, monitoring and evaluation, and preventive
chemotherapy campaigns. If funding was available for one
program, it may have been able to implement preventive
chemotherapy while its sister program could not. Research has
resulted in sufficient evidence to suggest that coimplementation is
safe for communities, feasible to implement, and efficient [44].
WHO has endorsed the coimplementation of mass drug
administration, an approach also referred to as the integrated
approach to preventive chemotherapy [54].
Ultimately sanitation and clean water are also critical for
sustaining the impact of control and elimination strategies that rely
on mass drug administration, but we must recognize the enormous
expense of such interventions and their poor track record in the
absence of parallel economic development [55]. Anthelminthic
vaccines are also under development, which will contribute
substantially to the sustainable elimination of the NTDs [56].
Indeed for some anthelminthic drugs there is also concern about
the emergence of drug resistance. However, for at least the next
decade we believe that integrated preventive chemotherapy offers
the greatest promise, particularly for Africa where NTD burdens
are the highest. By linking mass drug administration efforts for the
three major STH infections and schistosomiasis with those for
onchocerciasis, LF, and trachoma, it should be possible to
simultaneously attain high coverage for all seven NTDs
[28,57,58]. Bundling mass treatments for these conditions could
provide cost savings of up to 47% in what is already a low cost-
strategy [59]. The integration of NTD control builds on a number
of existing strengths including the donation of essential medicines,
the successful track record of the major public private partnerships
already committed to mass drug administration, the widespread
reach of CDTI even in post-conflict countries, and the
strengthening of health systems by empowering both health
ministries and volunteer community drug distributors [60].
Countries are currently being supported to adopt and scale-up
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private sector donors.
With only 3 years of implementation supported by USAID so
far, efficiencies are already being realized and tremendous scale-up
of control for the seven NTDs documented. In Sierra Leone, a
strong onchocerciasis program treated 12 districts in 2006 and
2007, and children ages 12–59 months were treated for STH
infections in 14 districts through Maternal and Child Health
Weeks (MCHW) in 2006 and 2007. The Ministry of Health and
Sanitation was able to build on the onchocerciasis and MCHW
platforms to begin treatment for schistosomiasis and has increased
by 117% the number of districts treated for LF and the number of
districts treating school-age children for STH infections. In Niger,
government commitment to expanding NTD control through an
integrated approach has resulted in the number of persons treated
for STH infections increasing by 254%, trachoma by 179%, and
schistosomiasis by 29%, between 2006 and 2008.
The relatively modest costs of integrated NTD control [56]
effectively mean that a little money goes a long way. In 2010 the
commitment of $65 million from the United States Government
(USG) for integrated NTD control, together with a commitment
from the United Kingdom, means that more than 100 million
people who would otherwise not have been treated could receive
essential NTD drugs next year. Efforts are now in place to
establish regional financing mechanisms for NTDs in Latin
America and the Caribbean through a trust fund at the
Interamerican Development Bank. In Africa, APOC with
WHO, World Bank and other development partners is exploring
how to integrate CDTI into national health systems and to support
country-led coimplementation efforts to control onchocerciasis
and other NTDs. Other mechanisms are also under consideration,
with similar discussions for Asia underway. More than a decade
ago the question was asked ‘‘can we deworm this wormy world?’’
referring to a landmark 1947 paper on the first global prevalence
assessment of helminth infections [61]. Integrated NTD control
represents the most cost-effective means to achieve global drug
coverage and attain this goal, as well as improve maternal and
child health, reduce blindness and disability, and ensure
elimination efforts in the foreseeable future.
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